A single short position worth $4.82 million in Ether (ETH) perpetual futures was liquidated on the OKX exchange at a price of $2,412 on October 20. This liquidation occurred because the position could no longer meet margin requirements, forcing its closure. The event highlights the risks of leveraged trading in volatile crypto markets, especially for large positions. This specific liquidation was a single event, not a sum of multiple liquidations, and reflects market dynamics at that time.
The story of a $4.82 million Ether short liquidation on OKX offers context for crypto market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 21, 2026 05:11 WIB: out of 50 priced major cryptocurrencies, 44 rose and 5 fell. Notable movers include VET (VeChain) at Rp129 with a 7.09% increase and balanced Pluang order activity (49% Sell / 51% Buy), MANA (Decentraland) at Rp1,583 up 5.67% with predominantly sell orders (87% Sell / 13% Buy), and COTI at Rp202 rising 5.32% with more sell activity (67% Sell / 33% Buy).
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
